Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Stock Buenos Aires S.E.

Equities

BMY

ARDEUT112877

Pharmaceuticals

End-of-day quote Buenos Aires S.E.
Other stock markets
 18:00:00 2024-06-02 EDT 		5-day change 1st Jan Change
18,116 ARS +6.42% Intraday chart for Bristol-Myers Squibb Company +3.10% +10.09%
03:31pm Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients MT
02:38pm Bristol Myers: positive results in liver cancer CF

Financials

Sales 2024 * 46.09B 41,318B 63.04B Sales 2025 * 46.06B 41,290B 63B Capitalization 84.67B 75,908B 116B
Net income 2024 * -5.41B -4,854B -7.41B Net income 2025 * 10.22B 9,162B 13.98B EV / Sales 2024 * 2.68 x
Net Debt 2024 * 39.03B 34,994B 53.39B Net Debt 2025 * 31.68B 28,398B 43.33B EV / Sales 2025 * 2.53 x
P/E ratio 2024 *
-15.9 x
P/E ratio 2025 *
7.9 x
Employees 34,100
Yield 2024 *
5.76%
Yield 2025 *
6.05%
Free-Float 69.27%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients MT
Bristol Myers: positive results in liver cancer CF
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies MT
Bristol Myers Squibb?S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting CI
Bristol Myers: presents advances in lung cancer CF
Bristol Myers Squibb Presents Multiple New Analyses At 2024 Asco® Annual Meeting Highlighting Opdivo and Opdivo-Based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer CI
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes RE
GSK blood cancer drug nearly halves risk of death in late-stage trial RE
Bristol Myers Squibb Announces Results from the Phase 3 KRYSTAL-12 Study Evaluating KRAZATI®? CI
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma MT
Bristol Myers: FDA approval for Breyanzi CF
US FDA allows use of Bristol's cell therapy for rare blood cancer RE
U.S. Food and Drug Administration Approves Bristol Myers Squibb?s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma CI
Bristol Myers Squibb’s Urothelial Carcinoma Combo Drug Gets EU Commission Approval MT
Bristol-Myers Squibb Gains EU Approval for Opdivo Combination Therapy for Urothelial Cancer MT
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial BU
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference BU
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting BU
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer BU
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : résultats positifs dans le cancer du foie
Bristol Myers : présente ses avancées en cancer du poumon
Bristol Myers : approbation de la FDA pour Breyanzi
Bristol Myers : nouvelle approbation de la CE pour Opdivo
Bristol Myers : présentera des données sur la schizophrénie
More news

Quotes and Performance

1 day+6.42%
1 week+3.10%
Current month+6.42%
1 month+10.13%
3 months-1.66%
6 months+20.19%
Current year+10.09%
More quotes

Highs and lows

1 week
15 950.00
Extreme 15950
18 293.00
1 month
15 680.00
Extreme 15680
18 293.00
Current year
15 680.00
Extreme 15680
22 442.50
1 year
10 600.00
Extreme 10600
22 442.50
3 years
3 512.00
Extreme 3512
22 442.50
5 years
632.33
Extreme 632.327
22 442.50
10 years
162.43
Extreme 162.4317
22 442.50
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 15-01-31
David Elkins DFI
 Director of Finance/CFO 55 19-11-19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19-11-19
Peter Arduini BRD
 Director/Board Member 59 16-03-31
Derica Rice BRD
 Director/Board Member 59 20-08-31
More insiders

Quotes

Date Price Change Volume
24-06-03 18,116 +6.42% 2,041
24-05-31 17,023 +4.01% 1,415
24-05-30 16,367 +0.08% 3,307
24-05-29 16,354 -2.16% 765
24-05-28 16,714 -4.87% 2,983

End-of-day quote Buenos Aires S.E., June 02, 2024

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
10:45am - American Society of Clinical Oncology Meeting - Abstract No #LBA4008
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.77 USD
Average target price
53.19 USD
Spread / Average Target
+27.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.53% 748B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.05% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.80% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.32% 325B
ABBVIE INC. Stock AbbVie Inc.
+4.92% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.47% 245B
NOVARTIS AG Stock Novartis AG
+9.17% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-4.21% 209B
PFIZER, INC. Stock Pfizer, Inc.
+2.80% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BMY Stock